Conference Coverage

VIDEO: Win-win with denosumab as adjuvant therapy for post-menopausal breast cancer


 

AT SABCS 2015

References

SAN ANTONIO – Adding denosumab to adjuvant aromatase inhibitor therapy, not only reduced risk of fracture, but also improved disease-free survival for postmenopausal patients with early-stage, hormone receptor–positive breast cancer, according to results presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Michael Gnant, professor of surgery at the Medical University of Vienna, discusses the phase III ABCSG-18 clinical trial, and why he will now be prescribing denosumab to HR-positive breast cancer patients who are receiving adjuvant aromatase inhibitor therapy, regardless of their bone health status.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

bjancin@frontlinemedcom.com

Recommended Reading

How to individualize cancer risk reduction after a diagnosis of DCIS
MDedge ObGyn
Partial breast irradiation valid option to prevent local recurrence
MDedge ObGyn
ACOG plans consensus conference on uniform guidelines for breast cancer screening
MDedge ObGyn
AHA: Candesartan protects against cardiotoxicity in breast cancer patients in PRADA
MDedge ObGyn
Antibody drug conjugate induces responses in heavily pretreated TNBC
MDedge ObGyn
No racial disparity in appropriate use of Oncotype DX
MDedge ObGyn
Racial differences found in neoadjuvant chemo, pCR rates for breast cancer
MDedge ObGyn
AHA: Older breast cancer patients more likely to die of heart disease than malignancy
MDedge ObGyn
Annual screening mammography beginning at age 40 saves the most lives
MDedge ObGyn
High risk for getting breast cancer linked with low risk of metastasis
MDedge ObGyn